Skip to main
  1. Stocks
  2. Kardigan Inc
  3. Forecast
KARD

Kardigan Inc (KARD) Stock Forecast & Price Target

Kardigan Inc (KARD) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kardigan is attractive fundamentally because it owns three late-stage cardiovascular programs aimed at large, underserved indications with no disease-modifying therapies, and each asset has prior human data that de-risks the pipeline. Danicamtiv has shown coherent improvements in LVEF, LVGLS, and LAFI in genetic DCM, ataciguat previously reduced aortic valve calcium progression by about 70% versus placebo in CAVS, and tonlamarsen achieved a 67% AGT reduction with favorable safety in ASH-related development work. Its roughly $591 million cash position should fund all three Phase 2b programs through topline readouts into Phase 3, while Prolaio’s over four million hours of physiologic data adds an additional, potentially differentiated trial-design advantage.

Bears say

Kardigan is viewed negatively because its lead tonlamarsen program missed the BP co-primary in KARDINAL, with both groups showing identical 6.7 mmHg office systolic BP reductions at Week 20 and only descriptive secondary findings, undermining confidence that greater AGT suppression adds meaningful clinical benefit. The active run-in design and absence of a true placebo-only arm cloud interpretation, but the fact that this remains the highest-risk program is compounded by the novelty of the ASH transition-of-care market, which has no approved therapies and unproven commercial adoption. Financially, Kardigan is still pre-revenue, reported about $661M cash as of 2Q26, and expects runway into 2028, yet it likely needs substantial additional funding while facing regulatory, competitive, and clinical development risk across all three Phase 2b assets.

Kardigan Inc (KARD) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kardigan Inc and is not a guaranteed prediction by Public.com or investment advice.

Kardigan Inc (KARD) Analyst Forecast & Price Prediction

Get the latest Kardigan Inc (KARD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Kardigan Inc (KARD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kardigan Inc (KARD) Forecast

Analysts have given Kardigan Inc (KARD) a Buy based on their latest research and market trends.

According to 8 analysts, Kardigan Inc (KARD) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kardigan Inc (KARD)


Kardigan Inc (KARD) Analyst Forecast & Price Prediction

Get the latest Kardigan Inc (KARD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Kardigan Inc (KARD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover KARD stock data and trends